Cannabis Law Report

APRIL 8, 2022

Later that year, Doblin sued the DEA for the first time. submitted his first DEA application to manufacture marijuana for use in medical research. To celebrate this, we invite you to take a trip down memory lane and review highlights from every year of our history. Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Cannabis Law Report

JULY 12, 2019

31) The United States DEA has stated that small amounts of other cannabinoids will also occur in all cannabis extracts, even those that purport to be CBD only – unless synthesized de novo, CBD isolate will always contain small amounts of THC when extracted from a plant. September 2004. 32: United States DEA. 30 (2): 187–96.(1998).

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Cannabis Law Report

MARCH 25, 2019

The DEA has made previous requests–in 2001 and 2006–to the FDA for an evaluation of marijuana. But DEA regulators determined after both of those reviews that marijuana should remain a Schedule I substance. 2003, 2004, 2007, 2008, Nov. 17, 2004 , 118 Stat. 6059, 6074, 6075, 6077(a), (b), 6253, Nov.

Banking 45

Banking Law Marijuana State Laws 45